BINV — BioInvent International AB Share News
0.000.00%
Last trade - 00:00- SEK1.59bn
- SEK1.14bn
- SEK226.50m
Brief: Transgene, BioInvent Report Positive Phase Ia Data On Oncolytic Virus BT-001 In Solid Tumours
Brief: BioInvent, Transgene Report Positive Phase 1a Data On Oncolytic Virus Bt-001 In Solid Tumors
Brief: Bioinvent Gets Patent In Japan Relating To Treatment Of Tumors
Brief: BioInvent Q4 Loss After Tax Unchanged At SEK 78.3 Mln
Brief: BioInvent International Gets $3 Mln Capital Equity Investment
Brief: BioInvent Receives Notice Of Allowance In US For Patent Covering Bi-1206, Bi-1607
Brief: BioInvent Gets FDA Ind Approval For Anti-Fcyriib Antibody BI-1607
Brief: Bioinvent Q3 Loss After Tax Widens To SEK 63.9 Million
Brief: Bioinvent Completes Planned Dose-Escalation
Brief: Bioinvent Q2 Profit After Tax At SEK 167.4 Mln
Brief: BioInvent, Transgene Announce Collaboration And Supply Agreement With MSD
Brief: Transgene And BioInvent Announce Positive Progress For BT-001
Brief: Bioinvent’S BI-1206 To Advance Into Expansion Stage Of Phase 1/2A Study In NHL
Brief: BioInvent Gets Milestone Payment From Bayer/Hope Medicine Licensing Agreement
Brief: Bioinvent Q1 Loss After Tax Narrows To SEK 67.7 Mln
Brief: Bioinvent Q4 Loss After Tax At SEK 78.8 Mln
CASI Pharmaceuticals jumps as partner BioInvent's lymphoma treatment gets orphan drug tag
Brief: Transgene And BioInvent Joint JITC Publication Shows Potential Of BT-001 Oncolytic Virus
Brief: BioInvent Posts Positive Early Data From Solid Cancer Trial